These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 14562863)

  • 1. Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy.
    Montaner JS; Côté HC; Harris M; Hogg RS; Yip B; Chan JW; Harrigan PR; O'Shaughnessy MV
    J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S85-90. PubMed ID: 14562863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA.
    Montaner JS; Côté HC; Harris M; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV
    Clin Infect Dis; 2004 Mar; 38 Suppl 2():S73-9. PubMed ID: 14986278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of blood concentration of mitochondrial DNA as a marker of toxicity in 157 consecutively recruited untreated or HAART-treated HIV-positive patients.
    Chiappini F; Teicher E; Saffroy R; Pham P; Falissard B; Barrier A; Chevalier S; Debuire B; Vittecoq D; Lemoine A
    Lab Invest; 2004 Jul; 84(7):908-14. PubMed ID: 15122308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral blood mitochondrial DNA/nuclear DNA (mtDNA/nDNA) ratio as a marker of mitochondrial toxicities of stavudine containing antiretroviral therapy in HIV-infected Malawian patients.
    Kampira E; Dzobo K; Kumwenda J; van Oosterhout JJ; Parker MI; Dandara C
    OMICS; 2014 Jul; 18(7):438-45. PubMed ID: 24816082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.
    Jones SP; Qazi N; Morelese J; Lebrecht D; Sutinen J; Yki-Jărvinen H; Back DJ; Pirmohamed M; Gazzard BG; Walker UA; Moyle GJ
    J Acquir Immune Defic Syndr; 2005 Dec; 40(5):565-72. PubMed ID: 16284533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens.
    Côté HC; Yip B; Asselin JJ; Chan JW; Hogg RS; Harrigan PR; O'Shaughnessy MV; Montaner JS
    J Infect Dis; 2003 Jun; 187(12):1972-6. PubMed ID: 12792876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line therapy and mitochondrial damage: different nucleosides, different findings.
    Blanco F; García-Benayas T; José de la Cruz J; González-Lahoz J; Soriano V
    HIV Clin Trials; 2003; 4(1):11-9. PubMed ID: 12577192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.
    Côté HC; Brumme ZL; Craib KJ; Alexander CS; Wynhoven B; Ting L; Wong H; Harris M; Harrigan PR; O'Shaughnessy MV; Montaner JS
    N Engl J Med; 2002 Mar; 346(11):811-20. PubMed ID: 11893792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and functional mitochondrial assessment of HIV-infected patients developing HAART-related hyperlactatemia.
    Garrabou G; Morén C; Gallego-Escuredo JM; Milinkovic A; Villarroya F; Negredo E; Giralt M; Vidal F; Pedrol E; Martínez E; Cardellach F; Gatell JM; Miró O
    J Acquir Immune Defic Syndr; 2009 Dec; 52(4):443-51. PubMed ID: 19779356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelets, a typical source of error in real-time PCR quantification of mitochondrial DNA content in human peripheral blood cells.
    Banas B; Kost BP; Goebel FD
    Eur J Med Res; 2004 Aug; 9(8):371-7. PubMed ID: 15337626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy.
    Haugaard SB; Andersen O; Pedersen SB; Dela F; Richelsen B; Nielsen JO; Madsbad S; Iversen J
    J Med Virol; 2005 Sep; 77(1):29-38. PubMed ID: 16032748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy.
    Saitoh A; Fenton T; Alvero C; Fletcher CV; Spector SA
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4236-42. PubMed ID: 17893156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine.
    Lonergan JT; McComsey GA; Fisher RL; Shalit P; File TM; Ward DJ; Williams VC; Hessenthaler SM; Lindsey L; Hernandez JE;
    J Acquir Immune Defic Syndr; 2004 Aug; 36(4):935-42. PubMed ID: 15220700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial assessment in asymptomatic HIV-infected paediatric patients on HAART.
    Morén C; Noguera-Julian A; Rovira N; Garrabou G; Nicolàs M; Cardellach F; Martínez E; Sánchez E; Miró O; Fortuny C
    Antivir Ther; 2011; 16(5):719-24. PubMed ID: 21817193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy.
    de Mendoza C; de Ronde A; Smolders K; Blanco F; Garcia-Benayas T; de Baar M; Fernández-Casas P; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2004 Mar; 20(3):271-3. PubMed ID: 15117449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of antiretroviral effect on mitochondrial DNA depletion among HIV-infected patients in Bali.
    Masyeni S; Sintya E; Megawati D; Sukmawati NMH; Budiyasa DG; Aryastuti SA; Khairunisa SQ; Arijana I; Nasronudin N
    HIV AIDS (Auckl); 2018; 10():145-150. PubMed ID: 30104903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosis.
    Miró O; Villarroya J; Garrabou G; López S; Rodríguez de la Concepción M; Pedrol E; Martínez E; Giralt M; Gatell JM; Cardellach F; Casademont J; Villarroya F
    Antivir Ther; 2005; 10(8):945-51. PubMed ID: 16430200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulatory mechanisms compensate for mitochondrial DNA depletion in asymptomatic individuals receiving stavudine plus didanosine.
    Miró O; López S; Rodríguez de la Concepción M; Martínez E; Pedrol E; Garrabou G; Giralt M; Cardellach F; Gatell JM; Vilarroya F; Casademont J
    J Acquir Immune Defic Syndr; 2004 Dec; 37(5):1550-5. PubMed ID: 15577406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naïve patients.
    Maagaard A; Holberg-Petersen M; Kvittingen EA; Sandvik L; Bruun JN
    HIV Med; 2006 Jan; 7(1):53-8. PubMed ID: 16313293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial DNA content of peripheral blood mononuclear cells in ART untreated & stavudine/zidovudine treated HIV-1-infected patients.
    Subashini D; Dinesha TR; Srirama RB; Boobalan J; Poongulali S; Chitra DA; Mothi SN; Solomon SS; Saravanan S; Solomon S; Balakrishnan P
    Indian J Med Res; 2018 Aug; 148(2):207-214. PubMed ID: 30381544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.